Therapeutic agents to prevent PPH in WBD
| Agent . | Type of study . | Dose, route . | Comparator . | Additional notes . |
|---|---|---|---|---|
| Uteronic agent27 | International expert panel | 3-5 IU, IV | — | First-line measure for uterine atony |
| TA33 | Randomized phase 3 trial | 1 g, IV | 0.9% NaCl | In vaginal delivery with oxytocin |
| TA32 | Meta-analysis | IV (various) | — | With uterotonic prophylaxis |
| TA31 | Randomized phase 3 trial | 1 g, IV | 0.9% NaCl | International study, no uterotonics. |
| rVWF/pdVWF40 | Pilot observational study | 80 IU/kg, IV | 50 IU/kg IV | In VWD, vaginal or cesarean delivery. |
| rVWF40 | Planned phase 3 trial | 120 IU/kg, IV | TA with or without rVWF | In VWD, vaginal or cesarean delivery. |
| Agent . | Type of study . | Dose, route . | Comparator . | Additional notes . |
|---|---|---|---|---|
| Uteronic agent27 | International expert panel | 3-5 IU, IV | — | First-line measure for uterine atony |
| TA33 | Randomized phase 3 trial | 1 g, IV | 0.9% NaCl | In vaginal delivery with oxytocin |
| TA32 | Meta-analysis | IV (various) | — | With uterotonic prophylaxis |
| TA31 | Randomized phase 3 trial | 1 g, IV | 0.9% NaCl | International study, no uterotonics. |
| rVWF/pdVWF40 | Pilot observational study | 80 IU/kg, IV | 50 IU/kg IV | In VWD, vaginal or cesarean delivery. |
| rVWF40 | Planned phase 3 trial | 120 IU/kg, IV | TA with or without rVWF | In VWD, vaginal or cesarean delivery. |
TA, tranexamic acid; —, no comparator.